EvaluatePharma® European Drug Forecasts Evaluate European Drug Forecasts to 2024: Real-world, country level historic product sales and consensus based forecasts.

Conduct European market sizing, R&D horizon scanning and price comparison utilising real world government and company reported sales data with country level, consensus based product forecasts to 2024.

Model Government European Future Pipeline and Company Market Sizing Impact Reported Forecasts for key Forecasts for full Drug Sales branded products R&D pipeline Compare with audit based systems

European Pricing Generic Market Launch Dates Perform Analysis Launch dates comparative Generic sales, for products pricing analysis volume & pricing in European countries Single solution for business development and licensing, commercial and corporate strategy, consultants and investment banks

Europe Product Forecasts (€m): Top 5 Brands in 2022 Anti-TNF Products

European Market Sizing Humira Enbrel Simponi Remicade Cimzia Other Tecentriq () Durvalumab (durvalumab) Margetuximab (margetuximab) 8,000 (olaratumab) PF-05280014 () Other 3,000 Forecasts for key branded drugs at a European country level – 7,000 market value of over €100bn in 2024 6,000 2,500 5,000 2,000

• Conduct future market assessment 4,000 1,500 Sales (€m) Sales (€m) 3,000 • Map future trends of key marketed drugs 1,000 2,000

500 • Profile in line products 1,000 0 0 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2016 2017 2018 2019 2020 2021 2022

Humira Enbrel Simponi Remicade Cimzia Other Tecentriq (atezolizumab) Durvalumab (durvalumab) Margetuximab (margetuximab) Europe8,000 R&D Product Forecasts: Olaratumab (olaratumab) PF-05280014 (trastuzumab) Other Antineoplastics 3,000 7,000 Model Future Pipeline Impact Humira Enbrel Simponi Remicade Cimzia Other Tecentriq (atezolizumab) Durvalumab (durvalumab) Margetuximab (margetuximab) 6,000 2,500 8,000 Olaratumab (olaratumab) PF-05280014 (trastuzumab) Other

5,0003,000 Full forecast pipeline for R&D products7,000 launching in Europe – 2,000

4,0002,500 Avastin Keytruda Herceptin Perjeta Opdivo 6,000 1,500 YERVOY market value €30bn Sales (€m) 100% Sales (€m) 95%3,000 5mg/ml Perf FL 40ml 14,000 5,000 2,000 (Unassigned Company) 90% 1,000 85%2,000 • Map key pipeline assets that are likely4,000 to launch by 2024 80% YERVOY 1,500 75% 5mg/ml500 Perf FL 10ml 3,500 Sales (€m) Sales (€m) 70%1,000 3,000 (Unassigned Company) 65% and measure impact 1,000 60% 0 0 ADCETRIS 2,000 55% 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 50mg Perf2016 FL 20173,150 2018 2019 2020 2021 2022 50% (Unassigned Company) 45%500 1,000 • Identify new medicines and how they impact therapy areas 40% 35% PERJETA 0 30% 0 420mg Perf FL 14ml 2,861 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 25% 2016 2017 2018 2019 2020 2021 2022 (Unassigned Company) 20% 15% KADCYLA 10% 100mg Perf FL Humira Enbrel Simponi Remicade Cimzia Other Tecentriq (atezolizumab) Durvalumab (durvalumab) Margetuximab (margetuximab) 1,798 5% (Unassigned Company) 8,000 Sales0 OlaratumabMarket (olaratumab) Share withinPF-05280014 Key (trastuzumab) Brands:Other 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 Monoclonal3,000 Antibody Antineoplastics 7,000

Competitive Landscaping 2,500 Avastin Keytruda Herceptin Perjeta Opdivo 6,000 100% YERVOY 95% 5mg/ml Perf FL 40ml 14,000 5,000 2,000 Historical government and company reported sales data 90% (Unassigned Company) 85% 4,000 80% YERVOY Avastin Keytruda Herceptin Perjeta Opdivo 1,500 75% YERVOY 5mg/ml Perf FL 10ml 3,500 Sales (€m) 100% Sales (€m) (EU 5 and other key markets) 70% (Unassigned Company) 95%3,000 5mg/ml Perf FL 40ml 14,000 (Unassigned65% Company) 90% 601,000% 85%2,000 ADCETRIS 55% 50mg Perf FL 3,150 • Compare product performance across80% key European markets 50% YERVOY 75% 5mg/ml500 Perf FL 10ml 3,500 (Unassigned Company) 1,000 45% 70% (Unassigned40% Company) 65% 35% PERJETA • Map uptake trends and drivers across60% 0European countries 30% 0 ADCETRIS 420mg Perf FL 14ml 2,861 55% 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 25% 50mg Perf2016 FL 20173,150 2018 2019 2020 2021 2022 (Unassigned Company) 50% (Unassigned20% Company) 45% 15% KADCYLA • 40% 10% 100mg Perf FL 1,798 Understand drug launch timelines across35% 20 countries PERJETA 5% (Unassigned Company) 30% 420mg Perf FL 14ml 2,861 (Unassigned0 Company) 25% 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 20% 15% KADCYLA 10% 100mg Perf FL 1,798 5% (Unassigned Company) 0 Manufacturer Price (France) € - Latest 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (€) Monoclonal Antibody Antineoplastics Pricing Comparison Analysis AcrossAvastin Keytruda CountriesHerceptin Perjeta Opdivo 100% YERVOY 95% 5mg/ml Perf FL 40ml 14,000 90% (Unassigned Company) Ex-factory pricing data for Germany, France,85% Italy, England, Poland, 80% YERVOY 75% 5mg/ml Perf FL 10ml 3,500 70% (Unassigned Company) Spain and other key markets 65% 60% ADCETRIS 55% 50mg Perf FL 3,150 50% (Unassigned Company) • Perform comparative analysis across45% EU 6 countries for key products 40% 35% PERJETA 30% 420mg Perf FL 14ml 2,861 • Use price/DDD benchmark to inform25% quick assessment of new assets (Unassigned Company) 20% 15% KADCYLA 10% 100mg Perf FL 1,798 5% (Unassigned Company) 0 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000

A pioneering methodology for European country level drug forecasts

Powered by Evaluate’s industry standard consensus forecasts and broken out on a European country level using: • European historical data – government and company reported • Coupled with Evaluate’s proprietary methodology inputs: – Estimated European launch timelines of R&D products – Analogue methodology to model forecast for R&D products – European uptake patterns and country launch timings – Expected European generic entry

Copyright © 2018 Evaluate Ltd. All rights reserved. Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2024 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support.

EvaluatePharma® delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance. @EvaluatePharma

EvaluateMedTech® sets a new standard in commercial analysis and consensus forecasts of the global medical device and diagnostic industry. @EvaluateMedTech

EvaluateClinical Trials® delivers unique clinical trial intelligence expertly curated to efficiently analyse the global clinical trial landscape. @EPClinicalTrial

EP Vantage an award winning editorial team, provides daily commentary and analysis with fresh perspectives and insight into current and future industry trends. @EPVantage

Evaluate Custom Services provides customised solutions to help you access, analyse and manage the information you need to support effective decision-making.

The Evaluate services enable the life science community to make sound business decisions about value and opportunity.

www.evaluate.com

Evaluate Headquarters Evaluate Americas Evaluate Asia Pacific Evaluate Ltd. EvaluatePharma USA Inc. Evaluate Japan KK 11-29 Fashion Street 60 State Street, Suite 1910 Akasaka Garden City 4F London E1 6PX Boston, MA 02109 4-15-1 Akasaka, Minato-ku United Kingdom USA Tokyo 107-0052 T +44 (0)20 7377 0800 T +1 617 573 9450 Japan F +44 (0)20 7539 1801 F +1 617 573 9542 T +81 (0)80 1164 4754 EUROPEAN DRUG FORECASTS – APR 2018